Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | MST1R | Q04912 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 3/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.59 |
| ▸ | HGF | P14210 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223147 | 0.89 | MET (0.58) | METKDRMST1RSRCTGFBR1 | |
| SCHEMBL372031 | 0.89 | AXL (0.61) | METKDRMST1RHGFAXL | |
| SCHEMBL21408242 | 0.89 | MET (0.58) | METKDRMST1RHGFAXL | |
| SCHEMBL30216641 | 0.89 | MET (0.58) | METKDRMST1RHGFAXL | |
| SCHEMBL31412927 | 0.89 | AXL (0.61) | METKDRMST1RHGFAXL | |
| Ammonia Solution, Strong SCHEMBL2063874 | 0.88 | MET (0.57) | METKDRMST1RSRCTGFBR1 | |
| SCHEMBL15338419 | 0.88 | SRC (0.70) | METKDRMST1RSRCTGFBR1 | |
| SCHEMBL16933077 | 0.88 | AXL (0.60) | METKDRMST1RHGFAXL | |
| SCHEMBL19711775 | 0.87 | MET (0.62) | METKDRMST1RAXLFGFR2 | |
| SCHEMBL13955464 | 0.87 | MET (0.57) | METKDRMST1RHGFAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | MET 2/4885KDR 5/4885MST1R 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.